Nintedanib may be effective in slowing the progression of interstitial lung disease
1. In this phase 3 trial, patients with fibrosing lung disease who received nintedanib experienced a much slower rate of ...
Tag: forced vital capacity (FVC)
The SENSCIS trial: nintedanib slows declines in FVC in patients with interstitial lung disease caused by systemic sclerosis
1. The SENSCIS trial, a randomized control trial studying the efficacy of nintedanib, an intracellular tyrosine kinase inhibitor, versus placebo ...